Xu Y - Search Results

1

Vitamin D Status Is Associated With Immune Checkpoint Inhibitor Efficacy and Immune-related Adverse Event Severity in Lung Cancer Patients: A Prospective Cohort Study.

You W, Liu X, Tang H, Lu B, Zhou Q, Li Y, Chen M, Zhao J, Xu Y, Wang M, Qian J, Tan B. You W, et al. Among authors: xu y. J Immunother. 2023 Jul-Aug 01;46(6):236-243. doi: 10.1097/CJI.0000000000000469. Epub 2023 May 16. J Immunother. 2023. PMID: 37184520

2

Gut microbiota composition in patients with advanced malignancies experiencing immune-related adverse events.

Liu X, Tang H, Zhou Q, Zeng Y, Lu B, Chen D, Li Y, Qian J, Chen M, Zhao J, Xu Y, Wang M, Tan B. Liu X, et al. Among authors: xu y. Front Immunol. 2023 Feb 20;14:1109281. doi: 10.3389/fimmu.2023.1109281. eCollection 2023. Front Immunol. 2023. PMID: 36891304 Free PMC article.

3

Immune checkpoint inhibitors for the treatment of non-small cell lung cancer brain metastases.

Wei Y, Xu Y, Wang M. Wei Y, et al. Among authors: xu y. Chin Med J (Engl). 2023 Jul 5;136(13):1523-1531. doi: 10.1097/CM9.0000000000002163. Chin Med J (Engl). 2023. PMID: 37106555 Free PMC article. Review.

4

Dynamic gut microbiota changes in patients with advanced malignancies experiencing secondary resistance to immune checkpoint inhibitors and immune-related adverse events.

Zeng Y, Shi Q, Liu X, Tang H, Lu B, Zhou Q, Xu Y, Chen M, Zhao J, Li Y, Qian J, Wang M, Tan B. Zeng Y, et al. Among authors: xu y. Front Oncol. 2023 Apr 11;13:1144534. doi: 10.3389/fonc.2023.1144534. eCollection 2023. Front Oncol. 2023. PMID: 37114123 Free PMC article.

5

The Presence of Lung Cancer Affects SARS-CoV-2 Vaccine Uptake and Attitude in Chinese Patients: A Clinical Cross-Sectional Investigation.

Chen C, Pan R, Dai L, Chen M, Zhao J, Zhong W, Wang M, Liu H, Xu Y, Han X. Chen C, et al. Among authors: xu y. Cancer Invest. 2023 Jul;41(6):601-616. doi: 10.1080/07357907.2023.2233624. Epub 2023 Jul 27. Cancer Invest. 2023. PMID: 37401814

6

[Immune Checkpoint Inhibitors Related Cystoureteritis: A Case Report and Literature Review].

Li S, Zheng K, Xu Y, Wang M. Li S, et al. Among authors: xu y. Zhongguo Fei Ai Za Zhi. 2023 Sep 20;26(9):709-716. doi: 10.3779/j.issn.1009-3419.2023.106.17. Zhongguo Fei Ai Za Zhi. 2023. PMID: 37985157 Free PMC article. Review. Chinese.

7

Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study.

Zhang D, Liu X, Shen F, Zhao D, Shi Y, Zhang H, Liu J, Gao X, Chen M, Zhao J, Zhong W, Gao J, He M, Liu Y, Yang X, Qin J, Tang Y, Mu X, Gu Y, Zhang S, Chen X, Pang L, Meng Q, Guo Y, Zhang Y, Li W, Xing P, Cheng Y, Xin T, Li Q, Li Y, Chen J, Gao F, Jin B, Rossi A, Adachi H, Guerrera F, Husain H, Xu Y, Wang M. Zhang D, et al. Among authors: xu y. Transl Lung Cancer Res. 2023 Nov 30;12(11):2229-2244. doi: 10.21037/tlcr-23-577. Epub 2023 Oct 26. Transl Lung Cancer Res. 2023. PMID: 38090527 Free PMC article.

8

The Clinical Analysis of Checkpoint Inhibitor Pneumonitis with Different Severities in Lung Cancer Patients: A Retrospective Study.

Huang H, Chen R, Xu Y, Fang N, Shao C, Xu K, Wang M. Huang H, et al. Among authors: xu k, xu y. J Clin Med. 2024 Jan 1;13(1):255. doi: 10.3390/jcm13010255. J Clin Med. 2024. PMID: 38202262 Free PMC article.

9

Efficacy and safety of azvudine in symptomatic adult COVID-19 participants who are at increased risk of progressing to critical illness: a study protocol for a multicentre randomized double-blind placebo-controlled phase III trial.

Tian X, Xu Y, Wang L, Dong C, Yan X, Fan J, Xie H, Zhang H, Wang J, Liu Y, Wang Y, Pan S, Wu A, Liu X, Yao C, Wang M. Tian X, et al. Among authors: xu y. Trials. 2024 Jan 22;25(1):77. doi: 10.1186/s13063-024-07914-3. Trials. 2024. PMID: 38254211 Free PMC article.

10

Case report: Checkpoint inhibitor pneumonitis with positive anti-melanoma differentiation-associated gene 5 antibodies in a patient with lung cancer.

Pan S, Xie H, Wang L, Wang Y, Zou M, Xu Y, Tian X, Fan J, Wang J. Pan S, et al. Among authors: xu y. Front Immunol. 2024 Jan 12;14:1309531. doi: 10.3389/fimmu.2023.1309531. eCollection 2023. Front Immunol. 2024. PMID: 38283343 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

67,476 results

Search Page